UK-based Pharmaceutical Profiles has appointed Dr Peter Scholes as vice president of pharmaceutical sciences. Dr Scholes will assume overall operational responsibility for formulation, analytical and manufacturing functions within the company. Pharmaceutical Profiles has also appointed Dr Andrew Rankin as chief scientific officer, developing the company's scientific innovation. Dr Rankin has spent 14 years in leadership roles with Pfizer, from pre-clinical and exploratory drug development through to successful global regulatory approvals. "We are extremely pleased to welcome two experts of such high calibre to the company and look forward to benefiting from their insight and experience as Pharmaceutical Profiles continues its business growth," Pharmaceutical Profiles chief executive Dr Mark Egerton said. Janet Miller has joined the US' fourth largest national pharmaceutical wholesaler, H.D. Smith, as generics division vice president and will lead the company's growing generics operation and direct negotiations with generics manufacturers. Miller brings to the new role more than 10 years of experience in generic pharmaceuticals and over 20 years' experience in the healthcare industry. She was previously the director of generic pharmaceutical trade relations at Caremark RX, which recently integrated its pharmacy services with CVS. Consort Medical, previously Bespak, has promoted Jon Glenn to chief executive from finance director. Glenn will replace Mark Throdahl, who is leaving the company after six years. "Jon has done an excellent job as finance director and the board is delighted to appoint him as CEO. He has a first class knowledge of the company and the leadership skills to take Consort Medical successfully into the future. I look forward to working with Jon to deliver the company's full potential," Consort Medical chairman John Robinson said. Glenn was appointed finance director in September last year and was previously the global head of finance at Celltech. Don Bailey has been made a permanent fixture at Questcor Pharmaceuticals, being named chief executive and president following seven months in the role of interim president. "Don's been instrumental in setting the foundation for Questcor's strategic redirection announced in August. Under his leadership as our interim president, Questcor is now profitable and generating positive cash flows after a history of operating losses," Questcor chairman Virgil Thompson said. Bailey has previously served as chief executive and president of Comarco. Sunesis Pharmaceuticals has named Dr Lesley Stolz as corporate and business development vice president. She will be responsible for overseeing the company's partnering and collaboration activities. Stolz joins Sunesis with more than a decade of biotechnology experience and has previously been business development senior director at GPC Biotech where she co-led the acquisition of Axxima Pharmaceuticals.